[Federal Register: January 26, 2005 (Volume 70, Number 16)]
[Notices]               
[Page 3709]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr26ja05-80]                         

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

 
Clinical Laboratory Improvement Advisory Committee

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Public Law 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting.

    Name: Clinical Laboratory Improvement Advisory Committee 
(CLIAC).
    Times and Dates:

8:30 a.m.-5 p.m., February 16, 2005.
8:30 a.m.-3 p.m., February 17, 2005.
    Place: Doubletree Hotel (Atlanta/Buckhead), 3342 Peachtree Rd. 
NE., Atlanta, Georgia 30326, Telephone: (404) 231-1234.
    Status: Open to the public, limited only by the space available. 
The meeting room accommodates approximately 100 people.
    Purpose: This committee is charged with providing scientific and 
technical advice and guidance to the Secretary of Health and Human 
Services, the Assistant Secretary for Health, and the Director, CDC, 
regarding the need for, and the nature of, revisions to the 
standards under which clinical laboratories are regulated; the 
impact on medical and laboratory practice of proposed revisions to 
the standards; and the modification of the standards to accommodate 
technological advances.
    Matters To Be Discussed: The agenda will include updates from 
the Food and Drug Administration, the Centers for Medicare & 
Medicaid Services, and the Centers for Disease Control and 
Prevention; implementation of cytology proficiency testing for 
individuals; a report from the CLIAC Workgroup on Good Laboratory 
Practices for Waived Testing, and discussion of the Workgroup's 
proposals related to such; and an introduction to appropriate 
quality control for diverse and evolving test systems, including 
microbiology identification systems. Agenda items are subject to 
change as priorities dictate.
    Providing Oral or Written Comments: It is the policy of CLIAC to 
accept written public comments and provide a brief period for oral 
public comments whenever possible. Oral Comments: In general, each 
individual or group requesting to make an oral presentation will be 
limited to a total time of five minutes (unless otherwise 
indicated). Speakers must also submit their comments in writing for 
inclusion in the meeting's Summary Report. To assure adequate time 
is scheduled for public comments, individuals or groups planning to 
make an oral presentation should, when possible, notify the contact 
person below at least one week prior to the meeting date. Written 
Comments: For individuals or groups unable to attend the meeting, 
CLIAC accepts written comments until the date of the meeting (unless 
otherwise stated). However, the comments should be received at least 
one week prior to the meeting date so that the comments may be made 
available to the Committee for their consideration and public 
distribution. Written comments, one hard copy with original 
signature, should be provided to the contact person below. Written 
comments will be included in the meeting's Summary Report.
    Contact Person for Additional Information: Rhonda Whalen, Chief, 
Laboratory Practice Standards Branch, Division of Laboratory 
Systems, Office of Public Health Partnerships, CDC, 4770 Buford 
Highway, NE, Mailstop F-11, Atlanta, Georgia 30341-3717; telephone 
(770) 488-8042; fax (770) 488-8279; or via e-mail at 
RWhalen@cdc.gov.

    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining 
to announcements of meetings and other committee management 
activities, for CDC and the Agency for Toxic Substances and Disease 
Registry.

    Dated: January 20, 2005.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 05-1390 Filed 1-25-05; 8:45 am]

BILLING CODE 4163-18-P